Neurotropic growth factors and glycosaminoglycan based matrices to induce dopaminergic tissue formation

Biomaterials

Volumn 67, Issue , 2015, Pages 205-213

  Schurig, Katja ^a,b   Zieris, Andrea ^c,d   Hermann, Andreas ^a,b   Freudenberg, Uwe ^c,d   Heidel, Sabine ^b   Grimmer, Milauscha ^c,d   Storch, Alexander ^a,b,c   Werner, Carsten ^c,d  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^d LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

Author keywords

Cell replacement; Glycosaminoglycan; Hydrogel; Neural stem cells; Neurotrophic growth factor

Indexed keywords

AMINO ACIDS; CELL CULTURE; DISEASE CONTROL; HYDROGELS; POLYETHYLENE GLYCOLS; STEM CELLS; TISSUE;

DOPAMINERGIC NEURONS; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCANS; GROWTH FACTOR; NEURAL STEM CELL; NEURONAL CIRCUITRIES; NEUROTROPHIC FACTORS; TYROSINE HYDROXYLASE;

NEURONS;

FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOSAMINOGLYCAN; GROWTH DIFFERENTIATION FACTOR; MACROGOL; NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; HEPARIN; HYDROGEL; MACROGOL DERIVATIVE; NERVE GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL FATE; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DOPAMINERGIC NERVE CELL; FEMALE; HYDROGEL; IN VITRO STUDY; MESENCEPHALON; MOUSE; NERVE FIBER GROWTH; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG RELEASE; FETUS; GLIA; METABOLISM; NEURITE; PROCEDURES; SYNTHESIS; TISSUE ENGINEERING;

MURINAE;

ANIMALS; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; DOPAMINERGIC NEURONS; DRUG LIBERATION; FEMALE; FETUS; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLYCOSAMINOGLYCANS; HEPARIN; HYDROGELS; MESENCEPHALON; MICE, INBRED C57BL; NERVE GROWTH FACTORS; NEURAL STEM CELLS; NEURITES; NEUROGLIA; POLYETHYLENE GLYCOLS; TISSUE ENGINEERING;

EID: 84939646700     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.029     Document Type: Article

References (43)

1. Bjorklund A., Lindvall O. Cell replacement therapies for central nervous system disorders. Nat. Neurosci. 2000, 3:537-544.
2. Martinez-Morales P.L., Revilla A., Ocana I., Gonzalez C., Sainz P., McGuire D., et al. Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev. 2013, 9:685-699.
3. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
4. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
5. Brundin P., Barbin G., Isacson O., Mallat M., Chamak B., Prochiantz A., et al. Survival of intracerebrally grafted rat dopamine neurons previously cultured in vitro. Neurosci. Lett. 1985, 61:79-84.
6. Brundin P., Barbin G., Strecker R.E., Isacson O., Prochiantz A., Bjorklund A. Survival and function of dissociated rat dopamine neurones grafted at different developmental stages or after being cultured in vitro. Brain Res. 1988, 467:233-243.
7. Kordower J.H., Rosenstein J.M., Collier T.J., Burke M.A., Chen E.Y., Li J.M., et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 1996, 370:203-230.
8. Kordower J.H., Freeman T.B., Chen E.Y., Mufson E.J., Sanberg P.R., Hauser R.A., et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 1998, 13:383-393.
9. Zawada W.M., Zastrow D.J., Clarkson E.D., Adams F.S., Bell K.P., Freed C.R. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res. 1998, 786:96-103.
10. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
11. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8935-8939.
12. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
13. Lu X., Hagg T. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. J. Comp. Neurol. 1997, 388:484-494.
14. Rosenblad C., Kirik D., Bjorklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 2000, 161:503-516.
15. Johansson M., Friedemann M., Hoffer B., Stromberg I. Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. Exp. Neurol. 1995, 134:25-34.
16. Beck K.D., Knusel B., Hefti F. The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 1993, 52:855-866.
17. Ferrari G., Minozzi M.C., Toffano G., Leon A., Skaper S.D. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev. Biol. 1989, 133:140-147.
18. Park T.H., Mytilineou C. Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF. Brain Res. 1992, 599:83-97.
19. Studer L., Tabar V., McKay R.D. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat. Neurosci. 1998, 1:290-295.
20. Runeberg-Roos P., Saarma M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann. Med. 2007, 39:572-580.
21. Woodbury M.E., Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J. Neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol. 2014, 9:92-101.
22. Majd S., Smardencas A., Parish C.L., Drago J. Development of an in vitro model to evaluate the regenerative capacity of adult brain-derived tyrosine hydroxylase-expressing dopaminergic neurons. Neurochem. Res. 2011, 36:967-977.
23. Hou J.G., Mytilineou C. Secretion of GDNF by glial cells does not account for the neurotrophic effect of bFGF on dopamine neurons in vitro. Brain Res. 1996, 724:145-148.
24. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
25. Kordower J.H., Isacson O., Leventhal L., Emerich D.F. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?. Prog. Brain Res. 2000, 127:414-430.
26. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9:1164-1172.
27. Koutsopoulos S., Zhang S. Long-term three-dimensional neural tissue cultures in functionalized self-assembling peptide hydrogels, matrigel and collagen I. Acta Biomater. 2013, 9:5162-5169.
28. Nakaji-Hirabayashi T., Kato K., Iwata H. Improvement of neural stem cell survival in collagen hydrogels by incorporating laminin-derived cell adhesive polypeptides. Bioconjug. Chem. 2012, 23:212-221.
29. Uemura M., Refaat M.M., Shinoyama M., Hayashi H., Hashimoto N., Takahashi J. Matrigel supports survival and neuronal differentiation of grafted embryonic stem cell-derived neural precursor cells. J. Neurosci. Res. 2010, 88:542-551.
30. Gujral C., Minagawa Y., Fujimoto K., Kitano H., Nakaji-Hirabayashi T. Biodegradable microparticles for strictly regulating the release of neurotrophic factors. J. Control. Release Off. J. Control. Release Soc. 2013, 168:307-316.
31. Herran E., Ruiz-Ortega J.A., Aristieta A., Igartua M., Requejo C., Lafuente J.V., et al. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease. Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 2013, 85:1183-1190.
32. Freudenberg U., Hermann A., Welzel P.B., Stirl K., Schwarz S.C., Grimmer M., et al. A star-PEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases. Biomaterials 2009, 30:5049-5060.
33. Tsurkan M.V., Chwalek K., Prokoph S., Zieris A., Levental K.R., Freudenberg U., et al. Defined polymer-peptide conjugates to form cell-instructive starPEG-heparin matrices in situ. Adv. Mater. 2013, 25:2606-2610.
34. Zieris A., Prokoph S., Levental K.R., Welzel P.B., Grimmer M., Freudenberg U., et al. FGF-2 and VEGF functionalization of starPEG-heparin hydrogels to modulate biomolecular and physical cues of angiogenesis. Biomaterials 2010, 31:7985-7994.
35. Zieris A., Prokoph S., Welzel P.B., Grimmer M., Levental K.R., Panyanuwat W., et al. Analytical approaches to uptake and release of hydrogel-associated FGF-2. J. Mater. Sci. Mater. Med. 2010, 21:915-923.
36. Storch A., Burkhardt K., Ludolph A.C., Schwarz J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J. Neurochem. 2000, 75:2259-2269.
37. Zieris A., Chwalek K., Prokoph S., Levental K.R., Welzel P.B., Freudenberg U., et al. Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. J. Control. Release Off. J. Control. Release Soc. 2011, 156:28-36.
38. Dromard C., Bartolami S., Deleyrolle L., Takebayashi H., Ripoll C., Simonneau L., et al. NG2 and Olig2 expression provides evidence for phenotypic deregulation of cultured central nervous system and peripheral nervous system neural precursor cells. Stem Cells 2007, 25:340-353.
39. Mateo J.L., van den Berg D.L., Haeussler M., Drechsel D., Gaber Z.B., Castro D.S., et al. Characterization of the neural stem cell gene regulatory network identifies OLIG2 as a multi-functional regulator of self-renewal. Genome Res. 2015, 25:41-56.
40. Boku S., Nakagawa S., Takamura N., Kato A., Takebayashi M., Hisaoka-Nakashima K., et al. GDNF facilitates differentiation of the adult dentate gyrus-derived neural precursor cells into astrocytes via STAT3. Biochem. Biophys. Res. Commun. 2013, 434:779-784.
41. Wood T.K., McDermott K.W., Sullivan A.M. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. J. Neurosci. Res. 2005, 80:759-766.
42. Strelau J., Unsicker K. GDNF family members and their receptors: expression and functions in two oligodendroglial cell lines representing distinct stages of oligodendroglial development. Glia 1999, 26:291-301.
43. Hermann A., Maisel M., Wegner F., Liebau S., Kim D.-W., Gerlach M., Schwarz J., Kim K.-S., Storch A. Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells 2006, 24:949-964.